Articles

Webminar: Prediction, Prevention, and Treatment of Cancer-Associated Thrombosis - Thu 13th Nov
News

Webminar: Prediction, Prevention, and Treatment of Cancer-Associated Thrombosis - Thu 13th Nov

This talk – Prediction, Prevention, and Treatment of Cancer-Associated Thrombosis – will be presented by MASAB Member Alok Khorana, and Mike Streik is serving as moderator for this important educational program.

Read More
Welcome Bayer
News

Welcome Bayer

We are delighted to welcome Bayer as our new sponsor, that supports us with an unrestricted educational grant. Welcome!

Read More
Direct oral anticoagulants for the treatment of cancer-associated thrombosis
Trial Update

Direct oral anticoagulants for the treatment of cancer-associated thrombosis

Two major randomized trials as well as a wealth of real-world data has impacted clinical practice. It is important to consider not simply trials evidence but also clinical practice data for context and for knowledge regarding patient preferences, outside of a trial setting.

Read More
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Methodology

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

The American Society of Clinical Oncology just published the new recommendations regarding VTE prophylaxis and treatment in patients with cancer

Read More
Cancer-associated Thrombosis at ASH 2019
News

Cancer-associated Thrombosis at ASH 2019

We are happy to announce that ASH will be sponsoring a Scientific Workshop on Cancer Associated Thrombosis.

Read More
Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy
Risk Factors

Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy

Approximately 4% of cancer patients have non-valvular atrial fibrillation (NVAF) and require anticoagulation for prophylaxis against embolic stroke.

Read More
Managing antiplatelet therapy in thrombocytopenic patients with hematological malignancy
Anticoagulation Drugs

Managing antiplatelet therapy in thrombocytopenic patients with hematological malignancy

The use of antiplatelet therapy, prescribed for acute and chronic ischemic arterial disease, is frequently encountered in cancer patients. A clinical vignette-based experiment was designed to mimic the clinical scenarios in which decision-making occurs.

Read More
Cancers as coagulant mosaics
Basic Mechanism

Cancers as coagulant mosaics

Cancers are potent inducers of abnormal blood clotting, which usually heralds a more aggressive course of the disease and poor prognosis...

Read More
Cancer associated thrombosis at ISTH: what not to miss
News

Cancer associated thrombosis at ISTH: what not to miss

What’s of interest for us cancer-associated thrombosis specialists?

Read More
ICTHIC at ISTH 2019 - come find us
News

ICTHIC at ISTH 2019 - come find us

This year ICTHIC Magazine is travelling all the way to Melbourne in order to attend the 26th ISTH.

Read More

Page 1 of 7